title: Managing enlarged prostate in primary care.
abstract: Assessment and treatment of benign prostatic hyperplasia, or enlarged prostate, has evolved considerably in recent years; clear evidence has accumulated for the progression of disease over time, the association between disease progression and negative outcomes, and the potential for medical management of this condition. Commensurate with the long-term preventive role of primary care, efforts can and should be made to treat the underlying condition of enlarged prostate as well as to manage the symptoms short-term. This review outlines evaluation of men presenting with lower urinary tract symptoms, examines the challenges for medical treatment and suggests how treatment choice can address these challenges.
authors.affiliation: Division of Urology, University of Maryland School of Medicine, Baltimore, MD, USA. mnaslund@smail.umaryland.edu
authors.forename: M J
authors.initials: MJ
authors.lastname: Naslund
authors.forename: F J
authors.initials: FJ
authors.lastname: Costa
authors.forename: M M
authors.initials: MM
authors.lastname: Miner
mesh_terms: D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use; D000368:Aged; D000465:Algorithms; D042944:Cholestenone 5 alpha-Reductase / Q000037:antagonists & inhibitors; D018450:Disease Progression; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D005194:Family Practice / Q000379:methods; D006801:Humans; D008297:Male; D008875:Middle Aged; D011470:Prostatic Hyperplasia / Q000175:diagnosis / Q000628:therapy*; D012017:Referral and Consultation; D012307:Risk Factors; D014570:Urologic Diseases / Q000209:etiology / Q000628:therapy
chemical_list: D000317:Adrenergic alpha-Antagonists; D004791:Enzyme Inhibitors; D042944:Cholestenone 5 alpha-Reductase